SYNE2

Across TCGA pan-cancer cohorts, SYNE2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SYNE2 data layer compared with 24 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SYNE2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SYNE2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where SYNE2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.586	0.177	.001	31	view →
CCRCC	DFS	Tertile	III,IV	0.946	0.499	.002	27	view →
HNSC	DFS	Median	III,IV	0.764	0.518	.005	12	view →
LSCC	OS	Quartile	All	0.899	0.659	.008	10	view →
COAD	DFS	Tertile	II,III,IV	1.000	0.920	.047	6	view →
LUAD	DFS	Quartile	All	0.395	0.735	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SYNE2–PDAC (DFS)

Open the PDAC breakdown →